Polyp characteristics at screening colonoscopy and post-colonoscopy colorectal cancer mortality: a retrospective cohort study - 17/05/23
Abstract |
Background and Aims |
Polyp size and high-grade dysplasia in polyps at screening colonoscopy are considered risk factors for post-colonoscopy colorectal cancer (PCCRC) development and death, which might be averted by surveillance colonoscopy. However, robust evidence backing these risk factors is lacking. We aimed to investigate whether polyp size or dysplasia grade is associated with PCCRC mortality.
Methods |
This was a retrospective study including individuals of the Austrian Quality Certificate for Screening Colonoscopy who underwent a colonoscopy between January 2007 and December 2020. We investigated the association of polyp size and dysplasia in polyps with PCCRC mortality according to Cox regression analysis. In addition, whether patients with certain polyp characteristics had similar risk for CRC death compared with the Austrian population was assessed by calculating standardized mortality ratios (SMRs).
Results |
A total of 316,001 individuals were included. After a median follow-up time of 5.27 years (95% confidence interval [CI], 5.25-5.29), a significant association of polyps 10 to 20 mm (hazard ratio, 4.00; 95% CI, 2.46-6.50; P < .001) as well as high-grade dysplasia (hazard ratio, 6.61; 95% CI, 3.31-13.2; P < .001) with PCCRC death was observed. PCCRC mortality was significantly lower than the expected CRC mortality in the general population in patients with polyps < 10 mm and without high-grade dysplasia (SMR, .27; 95% CI, .21-.33; P < .001), which was not observed for patients with polyps ≥10 mm or with high-grade dysplasia (SMR, 2.05; 95% CI, 1.64-2.57; P < .001).
Conclusions |
Polyp size ≥10 mm and high-grade dysplasia are associated with PCCRC mortality in screening patients. The data suggest that these patients might benefit most from surveillance colonoscopy.
Le texte complet de cet article est disponible en PDF.Abbreviations : CI, CRC, HGD, HR, ICD-10, PCCRC, SMR, SSL, WHO
Plan
| DISCLOSURE: Dr Trauner: Advisor for Abbvie, Albireo, BiomX, BI, Falk, Gilead, Genfit, Hightide, Intercept, Janssen, MSD, Novartis, Phenex, Pliant, Regulus, Siemens, and Shire. Grants from Albireo, Alnylam, Cymabay, Falk, Gilead, Intercept, MSD, Takeda, and Ultragenyx. Travel grants from Abbvie, Falk Foundation, Gilead, Intercept, and Janssen. Speakers bureau for BMS, Falk Foundation, Gilead, Intercept, MSD, and Roche. Property rights from The Medical Universities of Graz and Vienna, which have filed patents on medical use of norUDCA (co-inventor). All other authors disclosed no financial relationships.The Main Association of Statutory Insurance Institutions, the Austrian Society for Gastroenterology and Hepatology, and the Austrian Cancer Aid are supporting the Austrian quality certificate for screening colonoscopy (Qualitätszertifikat Darmkrebsvorsorge ). |
|
| DIVERSITY, EQUITY, AND INCLUSION: We worked to ensure gender balance in the recruitment of human subjects. The author list of this paper includes contributors from the location where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work. |
Vol 97 - N° 6
P. 1109 - juin 2023 Retour au numéro
Article précédent
- Cold snare EMR for the removal of large duodenal adenomas
- Hunter Wang, Mayenaaz Sidhu, Sunil Gupta, Oliver Cronin, Timothy O’Sullivan, Anthony Whitfield, Nicholas G. Burgess, Michael J. Bourke
- Nomogram as a novel predictive tool for lymph node metastasis in T1 colorectal cancer treated with endoscopic resection: a nationwide, multicenter study
- Yoshiki Kajiwara, Shiro Oka, Shinji Tanaka, Takahiro Nakamura, Shoichi Saito, Yosuke Fukunaga, Manabu Takamatsu, Hiroshi Kawachi, Kinichi Hotta, Hiroaki Ikematsu, Motohiro Kojima, Yutaka Saito, Masayoshi Yamada, Yukihide Kanemitsu, Shigeki Sekine, Shinji Nagata, Kazutaka Yamada, Nozomu Kobayashi, Soichiro Ishihara, Yusuke Saitoh, Kenji Matsuda, Kazutomo Togashi, Koji Komori, Megumi Ishiguro, Toshio Kuwai, Takashi Okuyama, Akihiro Ohuchi, Shinobu Ohnuma, Kazuhiro Sakamoto, Tamotsu Sugai, Kenji Katsumata, Hiro-o Matsushita, Hiro-o Yamano, Hirotsugu Eda, Toshio Uraoka, Naohiko Akimoto, Hirotoshi Kobayashi, Yoichi Ajioka, Kenichi Sugihara, Hideki Ueno
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?